Literature DB >> 28964415

Aortic Valve Replacement With Perceval Bioprosthesis: Single-Center Experience With 617 Implants.

Giovanni Concistrè1, Francesca Chiaramonti2, Giacomo Bianchi2, Alfredo Cerillo2, Michele Murzi2, Rafik Margaryan2, Pierandrea Farneti2, Marco Solinas2.   

Abstract

BACKGROUND: This study describes the clinical and echocardiographic outcomes in a large single-center cohort of patients who underwent aortic valve replacement (AVR) with a sutureless Perceval (LivaNova, Milan, Italy) aortic bioprosthesis.
METHODS: Between March 2011 and December 2015, 617 patients underwent AVR with a Perceval bioprosthesis. The mean age was 76 ± 7 years, 388 patients were female (63%), and the mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was 6.2% ± 5.4%. Concomitant procedures were mitral valve surgery (n = 74), tricuspid valve repair (n = 22), coronary artery bypass grafting (n = 42), myectomy (n = 3), and ascending aorta replacement (n = 2).
RESULTS: The 30-day mortality rate was 1.9% (12 of 617). A total of 475 of 516 (92%) patients who had isolated AVR underwent minimally invasive surgery with an upper ministernotomy (n = 81) or a right anterior minithoracotomy (n = 394) approach. Cardiopulmonary bypass and aortic cross-clamp times were 81.7 ± 29.1 minutes and 50.5 ± 19.8 minutes for isolated AVR and 139.7 ± 51.5 minutes and 91.5 ± 29.5 minutes for combined procedures, respectively. At mean follow-up of 16.3 months (range, 0 to 51.9 months), the survival rate was 91.3%, the rate of freedom from reoperation was 99%, and the mean transvalvular pressure gradient was 11.9 ± 5.4 mm Hg. Left ventricular ejection fraction increased from 53.6% ± 8.4% to 54.5% ± 4.8% (p = 0.40), left ventricular mass decreased from 146.5 to 112.6 g/m2 (p < 0.001), and moderate paravalvular leakage occurred in 3 patients without hemolysis who did not require any treatment.
CONCLUSIONS: AVR with the Perceval bioprosthesis is associated with low mortality rates and excellent hemodynamic performance. Sutureless technology may reduce operative times, especially in combined procedures, and may make minimally invasive AVR more easily reproducible.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28964415     DOI: 10.1016/j.athoracsur.2017.05.080

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  Paravalvular Leaks-From Diagnosis to Management.

Authors:  Samuel Bernard; Evin Yucel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

2.  Right anterior mini-thoracotomy and sutureless valves: the perfect marriage.

Authors:  Marco Solinas; Giacomo Bianchi; Francesca Chiaramonti; Rafik Margaryan; Enkel Kallushi; Tommaso Gasbarri; Filippo Santarelli; Michele Murzi; Pierandrea Farneti; Alessandro Leone; Simone Simeoni; Egidio Varone; Federica Marchi; Mattia Glauber; Giovanni Concistrè
Journal:  Ann Cardiothorac Surg       Date:  2020-07

3.  Mid-term assessment of structural valve deterioration of perceval S sutureless prosthesis using the last European consensus definition.

Authors:  José Manuel Martínez-Comendador; Francisco Estevez-Cid; Miguel González Barbeito; Carlos Velasco García De Sierra; Alberto Bouzas Mosquera; Cayetana Barbeito; José Cuenca Castillo; José Herrera-Noreña
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-04-19

4.  A pooled analysis of pacemaker implantation after Perceval sutureless aortic valve replacement.

Authors:  Marco Moscarelli; Giuseppe Santarpino; Thanos Athanasiou; Pasquale Mastroroberto; Khalil Fattouch; Giuseppe Nasso; Giuseppe Speziale
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04

5.  Clinical outcomes after implantation of a sutureless aortic bioprosthesis with concomitant mitral valve surgery: the SURE-AVR registry.

Authors:  Max Baghai; Mattia Glauber; Raphael Fontaine; Jose Cuenca Castillo; Antony H Walker; Ugolino Livi; José Montiel; Alistair Royse; Gianluigi Bisleri; Davide Pacini; Vincenzo Argano; Aurelien Roumy; George Asimakopoulos; Marco Solinas
Journal:  J Cardiothorac Surg       Date:  2021-05-30       Impact factor: 1.637

Review 6.  Cardiac prostheses-related hemolytic anemia.

Authors:  Mohamad Alkhouli; Ali Farooq; Ronald S Go; Sudarshan Balla; Chalak Berzingi
Journal:  Clin Cardiol       Date:  2019-05-06       Impact factor: 2.882

7.  Changes in the Prosthesis Types Used for Aortic Valve Replacement after the Introduction of Sutureless and Rapid Deployment Valves in Korea: A Nationwide Population-Based Cohort Study.

Authors:  Hyeok Sang Woo; Ho Young Hwang; Ho Jin Kim; Joon Bum Kim; Sak Lee; Cheong Lim; Byung-Cheul Chang; Na Rae Lee; Youshin Suh; Jae Woong Choi
Journal:  J Chest Surg       Date:  2021-10-05

8.  Hemodynamic Performance of Sutureless vs. Conventional Bioprostheses for Aortic Valve Replacement: The 1-Year Core-Lab Results of the Randomized PERSIST-AVR Trial.

Authors:  Theodor Fischlein; Elena Caporali; Federico M Asch; Ferdinand Vogt; Francesco Pollari; Thierry Folliguet; Utz Kappert; Bart Meuris; Malakh L Shrestha; Eric E Roselli; Nikolaos Bonaros; Olivier Fabre; Pierre Corbi; Giovanni Troise; Martin Andreas; Frederic Pinaud; Steffen Pfeiffer; Sami Kueri; Erwin Tan; Pierre Voisine; Evaldas Girdauskas; Filip Rega; Julio García-Puente; Laurent De Kerchove; Roberto Lorusso
Journal:  Front Cardiovasc Med       Date:  2022-02-18

9.  Sutureless aortic valve replacement in high-risk patients with active infective endocarditis.

Authors:  Alina Zubarevich; Arian Arjomandi Rad; Marcin Szczechowicz; Arjang Ruhparwar; Alexander Weymann
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

10.  Sutureless aortic valve replacement in multivalve procedures.

Authors:  Alina Zubarevich; Marcin Szczechowicz; Konstantin Zhigalov; Anja Osswald; Jef Van den Eynde; Arian Arjomandi Rad; Robert Vardanyan; Daniel Wendt; Bastian Schmack; Arjang Ruhparwar; Alexander Weymann
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.